Studies about ProPublica's Surgeon Scorecard, urology participation in accountable care organizations, and Twitter were among the take-home messages in outcomes analysis at the 2016 AUA annual meeting. The take-homes were presented by Christopher Saigal, MD, MPH, of the University of California, Los Angeles.
There is no excess risk of death, prostate cancer diagnosis, or cardiovascular events with long-term testosterone replacement therapy, Canadian researchers have found in a population-based matched cohort study.
Concordance with National Cancer Comprehensive Network recommendations about follow-up during active surveillance for low-risk prostate cancer is generally low across urology practices in Michigan, reported researchers from the Michigan Urological Surgery Improvement Collaborative at the AUA annual meeting in San Diego.
A Veterans Administration Cooperative Study investigating chemotherapy after prostatectomy for high-risk prostate cancer was underpowered to show a statistically significant benefit of early adjuvant chemotherapy versus observation as the standard of care in the primary endpoint analysis of progression-free survival.
Four-year data on the prostatic urethral lift (UroLift) and data on a new water-jet ablation treatment were among BPH/LUTS highlights from this year’s meeting.
Microdissection testicular sperm extraction retrieval rates, adolescent varicocele repair, and evaluation of testosterone replacement therapy and prostate cancer are additional noteworthy topics in this field.
Fusion biopsy, salvage versus adjuvant radiation therapy, and superextended versus extended pelvic lymph node dissection are also covered in the take home messages on prostate cancer from the 2016 AUA annual meeting.
The authors of a recent NEJM letter question the validity of the controversial Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
An academic center/community practice collaboration increases use of surveillance among prostate cancer patients “through use of provider education and a standardized report card,” a study author said.
In this video, Neil Baum, MD, compares UroLift with other BPH management strategies and also discusses his experience with the use of nitrous oxide as an effective sedative during in-office urologic procedures.
This video demonstrates UroLift placement under topical anesthesia in the office setting and also includes comments from several patients who underwent the procedure.
This video provides an overview of the prostatic urethral lift (UroLift), highlighting the entire cycle of patient care.
Expression of androgen receptor splice variant 7 (AR-V7) in whole blood predicts worse cancer-related outcomes in patients with metastatic castration-resistant prostate cancer who are treated with abiraterone acetate (ZYTIGA).
"With all this uncertainty, the good news is that men will no longer need to travel to Canada or elsewhere for prostate HIFU therapy," writes Leonard G. Gomella, MD.
The ACA is a large step forward in allowing men to embrace their health concerns, and for health care practitioners to understand men and the challenge of help seeking, masculinity, and disparity in their quest for wellness (Men’s Health in Primary Care [Current Clinical Practice]. Switzerland: Springer International Publishing, 2016).
In a study of intralesional collagenase clostridium histolyticum, mean curvature was reduced most dramatically after the first cycle, researchers reported.
Paradoxically, the authors of a large study did not find a negative effect in functional outcomes analyzed.
Transrectal HIFU shows a statistically significant increase in per-core negative biopsy rates.
A CMS quality measure needs to be bidirectional, “specifying a rate of observation for low-risk disease and a rate of treatment for high-risk disease,” researchers say.
An image-guided technique for treating LUTS associated with BPH is reproducible and promising, researchers say.
A retrospective analysis looks at the short-term morbidity associated with transfusion among patients in the National Surgical Quality Improvement database.
Large study examines surveillance results in men with very low-, low-, intermediate-, and high-risk disease.
Specific clones may have the potential for grade conversion, research suggests.
No significant relationship was found between use of a phosphodiesterase type-5 inhibitor and prostate cancer recurrence after treatment in a nested case-control study.
High-intensity focused ultrasound as salvage therapy allows for intermediate-term disease control in selected patients with recurrence following radiation therapy for prostate cancer.
